tipifarnib
tipifarnib: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kura Oncology, Inc. (KURA) | Phase 2 |
Clinical Trials (1)
A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Frequently asked questions
Who is developing tipifarnib?
tipifarnib is being developed by Kura Oncology, Inc..
How many clinical trials involve tipifarnib?
BioSniper tracks 1 clinical trial involving tipifarnib.
Get deeper analysis on tipifarnib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis